São Paulo State is the clear center of Brazil’s pharmaceutical industry. It is home to the biggest and most important drug companies in the country. São Paulo is the center of production, innovation, business and it is also where the labs that make the medicines that millions of Brazilian households get every day are located.
In 2025, the Brazilian pharmaceutical market was worth about R$146.8 billion, which was 12% more than the year before. This total includes R$83.9 billion from domestic manufacturers, which is 58% of the market revenue and an impressive 80% of the volume. Local labs make eight out of ten medicines sold in Brazil. Brazilian companies have 94% of the market in the generics segment, which shows how strong this dominance is.
This carefully chosen list includes five outstanding pharmaceutical companies based in São Paulo. They were chosen based on their market leadership, revenue, size of operations, industry recognition and strategic importance to Brazil’s healthcare system. These companies are the best in São Paulo’s pharmaceutical industry, whether you’re an investor searching for opportunities, a healthcare professional looking for partners, or an industry observer looking to compare competitors.
How We Selected the Top Pharmaceutical Companies in São Paulo
We evaluated the companies featured in this list using the following general criteria:
- Market Leadership and Revenue: How big your business is and how well it does in Brazil
- Manufacturing Capacity: the infrastructure, facilities and geographic area needed for production
- Product Portfolio: A wide range of therapeutic categories and market segments (generic, branded and reference drugs)
- Innovation and R&D Investment: a promise to invest in research, development and new technologies
- Recognition in the industry: awards, rankings and a good name among doctors and patients
- Strategic Importance: Role in Brazil’s health sovereignty and ability to make things at home
List of Top 5 São Paulo-Based Pharmaceutical Companies
- EMS (Grupo NC)
- Hypera Pharma
- Aché Laboratórios
- Eurofarma
- Biolab
A Closer Look at Each Pharmaceutical Company
1. EMS (Grupo NC)
EMS is Brazil’s largest drug company, with the most sales and the most money made. As Grupo NC’s main pharmaceutical company, EMS has strengthened its position by making smart purchases and always investing in its production capacity. The company recently made headlines when it bought Medley from France’s Sanofi for R$3.6 billion, which solidified its position as the leader in the generics market.
Company Overview
Headquartered in Hortolândia, São Paulo, EMS is part of Grupo NC, a diversified conglomerate founded by the Sanchez family with 10,000 direct employees. The group includes recognized pharmaceutical brands such as EMS, Legrand, Germed, Multilab Farma and Novamed, making it the largest pharmaceutical group in Brazil.
After buying Medley, EMS will have about 31% of the generics market, which is an increase of 7–8% from its current 23–24%. The company has said that it will invest R$1 billion in expanding its factories in the following years.
Key Therapeutic Areas and Products
EMS has a wide range of products in many different therapeutic categories. The company’s brands, Germed, Legrand and EMS, make everything from over-the-counter medicines to prescription drugs. The Medley purchase adds a lot of manufacturing capacity, including a factory in Campinas, São Paulo.
Notable Strengths or Differentiators
EMS has won the Folha Top of Mind award for 2025, making it the most recognized brand in the world. It has done this every year since 2020. Veja Negócios also named the company one of Brazil’s Top 30 Best Companies in 2025 and the best in the pharmaceutical industry.
The company’s partnerships with organizations like Hospital Pequeno Príncipe and Hospital de Amor, which support pediatric oncology and early cancer detection programs, show how dedicated it is to research and innovation. Grupo NC, one of Brazil’s biggest business groups, is involved in telecommunications, energy and real estate development. EMS benefits from this group’s financial strength and strategic vision.
Contact Information
Website: www.gruponc.net.br
2. Hypera Pharma
Hypera Pharma is one of Brazil’s largest and most diversified pharmaceutical companies, present in all relevant segments of the sector with leadership positions across numerous categories. The company combines a portfolio of trusted brands with one of the country’s most modern pharmaceutical research centers.
Company Overview
Hypera Pharma is based in São Paulo at Avenida Magalhães de Castro, 4800, in the Cidade Jardim neighborhood. It has between 5,001 and 10,000 employees. The company has been on the Novo Mercado of B3 (Brazil’s stock exchange) since 2008 and has more than 3,400 direct employees.
Brainfarma, a subsidiary of the company, is where most of its research and development work takes place. It is home to one of Brazil’s largest and most modern pharmaceutical research centers. This facility has highly trained staff, including master’s- and doctorate-level researchers, who use the latest technology to make medicines, dermocosmetics and health products.
Key Therapeutic Areas and Products
Hypera Pharma makes a wide range of products, including prescription drugs, over-the-counter drugs, dermocosmetics and health products for consumers. The company’s varied approach lets it stay on top in many areas by offering products that stand out for their quality and safety, which is supported by ongoing investment in new ideas.
Notable Strengths or Differentiators
Hypera Pharma’s biggest strength is its ability to perform a wide range of activities, including research. The company’s mission, “para que as pessoas vivam mais e melhor” (so that people live longer and better), shows how dedicated it is to sustainable growth and new ideas. Hypera Pharma is a leader in bringing new treatments to the Brazilian market because it is home to one of Brazil’s best pharmaceutical research centers.
The company’s financial performance shows that it is the market leader. As of January 2026, its revenue was about $1.5 billion, making it one of the top pharmaceutical companies in Brazil. Its presence in all relevant pharmaceutical segments gives it strength and many ways to grow.
Contact Information
Website: www.hypermarcas.com.br
3. Aché Laboratórios
Aché Laboratórios is one of Brazil’s most respected pharmaceutical companies. It has been around for decades and is known for making high-quality products that doctors in many fields trust. In surveys of doctors’ opinions, the company has always been one of the best laboratories.
Company Overview
Aché is based in São Paulo and has a large manufacturing presence as well as a wide range of therapeutic classes in its portfolio. Experts in cardiology, gynecology, pediatrics, dermatology, orthopedics and clinical medicine have praised the company for its dedication to quality and new ideas.
Key Therapeutic Areas and Products
Aché sells a wide range of medicines, including prescription drugs, generic drugs and over-the-counter drugs. The company has become very strong in therapeutic areas where long-term relationships with patients and trust from doctors are very important. The 9th edition of the “Performance Farmacêutica 2025” study by Ipsos and Sindusfarma found that Aché was known for the quality of its products in many fields:
- Cardiologists and psychiatrists put it in third place.
- Otorhinolaryngologists and gynecologists put it in second place.
- Third place among dermatologists and orthopedists
- Pediatricians and general practitioners put it at the top of their lists.
- Neurologists and endocrinologists also know about this.
Notable Strengths or Differentiators
Aché’s consistent recognition across a wide range of medical specialties is remarkable, showing that he is good at many things instead of just one. Pediatricians and general clinicians, who treat a wide range of patients, give the company top marks, demonstrating that its portfolio is reliable and trustworthy.
The company has been in the Brazilian market for a long time and is dedicated to research and development. This makes it a top choice for doctors looking for high-quality medicines for their patients. Aché’s strong ties to the medical community and the trust that doctors have in its products are shown by how well it does in physician perception surveys.
Contact Information
Website: https://www.ache.com.br/
4. Eurofarma
Eurofarma is a major player in the pharmaceutical industries of Brazil and Latin America. They have a wide range of over 700 products that cover many therapeutic classes, including oncology. The company fills a lot of market prescriptions because it has a strong manufacturing presence in Brazil and all of Latin America.
Company Overview
Eurofarma started in 1972 and has grown to become one of Brazil’s biggest drug companies, with more than 10,000 workers. The company’s large manufacturing presence in Latin America lets it serve many markets while still meeting the high production standards expected of a top regional player.
Eurofarma’s portfolio includes a wide range of therapeutic categories, so they can meet all of your healthcare needs. The company’s scale and diversification have positioned it as a key supplier to Brazil’s healthcare system.
Key Therapeutic Areas and Products
With over 700 products in its portfolio, Eurofarma maintains a presence across virtually all major therapeutic classes. The company’s inclusion of oncology in its offerings demonstrates its commitment to high-complexity, high-value medications alongside more traditional pharmaceutical products.
The “Performance Farmacêutica 2025” study found that pediatricians and orthopedists praised Eurofarma for the quality of its products and that general clinicians ranked it third. This recognition in many fields shows how broad and consistent its portfolio is.
Notable Strengths or Differentiators
The fact that Eurofarma operates on a regional scale is what sets it apart. The company has factories all over Latin America, which gives it operational capabilities that go beyond Brazil’s borders. This makes it a true regional player instead of just a domestic manufacturer.
The company has been around since 1972, which gives it more than 50 years of experience in the market, knowledge of institutions and regulatory expertise. Eurofarma can keep product quality and supply reliability high while dealing with Brazil’s complicated regulatory environment because it has a lot of experience and keeps investing in research and development.
Contact Information
Website: https://eurofarma.com/
5. Biolab
Biolab is one of Brazil’s top pharmaceutical companies by revenue. As of January 2026, it had about $2 billion in annual revenue, which put it at the top of the revenue-based rankings. The company’s strong financial results show that its portfolio and market position are working well.
Company Overview
Headquartered in São Paulo, Biolab operates with 1,000-5,000 employees and has established itself as a major force in the Brazilian pharmaceutical industry. The company’s revenue leadership—ranking first among pharmaceutical manufacturers in Brazil in terms of revenue—demonstrates the commercial success of its product portfolio and commercial strategy.
Biolab’s interest in buying Medley from Sanofi shows its financial capacity and growth ambition. Even though EMS ended up winning the deal, Biolab’s participation in the competitive process shows that it is a major player in the industry that can make billion-real acquisitions.
Key Therapeutic Areas and Products
Biolab’s strong revenue performance shows that it has successfully positioned itself in many categories, even though specific therapeutic focus areas are not as well documented as those of some competitors. The company keeps a portfolio that doctors trust and that always has a lot of demand.
Notable Strengths or Differentiators
The most important thing that sets Biolab apart is its strong revenue leadership. The company makes about $2 billion a year in sales and its commercial success puts it at the top of the Brazilian industry. This financial strength provides the company the money it needs for research and development, business growth and smart purchases.
The company’s willingness to compete for big assets like Medley shows that it has big plans and is confident in its ability to integrate and grow the businesses it acquires. Even if Biolab doesn’t win that specific deal, its involvement in the process shows that it is one of Brazil’s top pharmaceutical companies.
Contact Information
Website: https://www.biolabeco.com.br/en/
How to Choose the Right Pharmaceutical Partner in São Paulo
- Define Your Engagement Type: Determine whether you seek commercial partnerships, investment opportunities, research collaboration, or supply agreements. Each company has different strategic priorities and openness to various forms of engagement.
- Evaluate Portfolio Alignment: Match your therapeutic area of interest with company strengths. Aché demonstrates broad physician recognition across multiple specialties. EMS leads in generics with a dominant market share. Hypera Pharma offers a diversified presence across all segments.
- Consider Manufacturing Scale: For supply agreements, evaluate production capacity and geographic footprint. EMS’s expanded capacity following the Medley acquisition and announced R$1 billion investment program signals significant manufacturing scale. Eurofarma’s regional presence across Latin America offers multi-country supply capability.
- Assess Innovation Capability: For research partnerships, evaluate R&D infrastructure. Hypera Pharma’s Brainfarma research center represents one of Brazil’s most advanced pharmaceutical research facilities. Partnerships with leading research hospitals reflect EMS’s commitment to innovation.
- Examine the market position and stability. Companies that make a lot of money, like Biolab, which makes $2 billion a year, are beneficial partners for the long term because they are financially stable. After buying Medley, EMS became the market leader in generics, which gives it pricing power.
- Check for compliance with regulations: All of the top companies strictly obey the rules set by ANVISA, Brazil’s health regulatory agency. Ask for proof of certifications, inspection histories and quality systems.
- Think about how well it fits with your organization’s values, long-term goals and commitments to sustainability. Being named one of Brazil’s Top 30 Best Companies shows that EMS is a wonderful company in more ways than just making money.
The pharmaceutical industry in São Paulo State is one of Brazil’s most successful industrial sectors. It has world-class manufacturing capabilities, cutting-edge research and a profound understanding of the domestic market. The five companies highlighted—EMS, Hypera Pharma, Aché, Eurofarma and Biolab—show how deep and complex this ecosystem is.
Brazil’s largest drug company is EMS. After buying Medley and getting a lot of attention from customers, including the Folha Top of Mind award, it now has a big share of the generics market. Hypera Pharma has one of Brazil’s most advanced research centers and sells a wide range of high-quality pharmaceutical products. Aché has the best products in more medical fields than any other company, so it has the most trusted doctors. Eurofarma is in Latin America and makes more than 700 products for the region. Biolab is a leader in business, with sales of about $2 billion a year and big plans for the future.
There are pros and cons to each company. The best one for you will depend on what you want to do, like getting generic drugs, making new drugs, starting a business partnership, or making a smart investment. The pharmaceutical leaders in São Paulo are still in charge of an industry that makes eight out of ten medicines sold in Brazil.
We encourage you to learn more about these companies, talk to their business and commercial development teams and find out how Brazilian pharmaceutical excellence can meet your needs in one of the world’s most dynamic healthcare markets.
FAQ
1. How large is the Brazilian pharmaceutical market?
The Brazilian pharmaceutical market was worth about R$146.8 billion in 2025, which was 12% more than the year before. Domestic manufacturers made R$83.9 billion (58% of revenue) and sold eight out of ten medicines, or 80% of the total.
2. What is the market share of generics in Brazil?
Generics make up a big and growing part of the Brazilian market. Brazilian labs sold 2.2 billion units in this category, which is 94% of the total of 2.4 billion units. In terms of money, domestic companies made R$20.85 billion, which is about 91% of the R$23 billion generics market.
3. How do Brazilian pharmaceutical companies compare to multinationals?
Domestic companies sell the most units (80%), but multinational companies are better at making new, high-value products. Brazilian companies generate 58% of the revenue, while multinational companies account for 42%. Over the past two decades, laboratories in the United States have grown much faster than those owned by people from other countries.
4. What was the significance of the EMS-Medley acquisition?
EMS’s R$3.6 billion purchase of Medley from Sanofi makes the Brazilian company the clear leader in generics, giving it about 31% of the market. The deal makes Brazilian drug companies stronger and keeps control of a key sector in Brazil.
5. Are São Paulo pharmaceutical companies involved in research and development?
Yes, large companies spend a lot of money on research and development. Hypera Pharma’s Brainfarma subsidiary runs one of Brazil’s largest and most up-to-date pharmaceutical research centers, where researchers have master’s and doctorate degrees. EMS does research with some of the best hospitals and has said it will spend R$1 billion to grow its business.
6. Which companies have the highest recognition among Brazilian physicians?
The “Performance Farmacêutica 2025” study found that Aché had the most recognition in cardiology, psychiatry, otorhinolaryngology, gynecology, dermatology, orthopedics, pediatrics and general medicine. Other companies, like Eurofarma, EMS and Libbs, also got awards in certain areas.
7. How is the pharmaceutical market expected to evolve in 2026?
Laboratories’ ongoing investments in expanding production and developing new technologies help drive growth expectations for 2026. The federal government’s new drug pricing rules should make it easier for incremental innovations to get off the ground. The expected end of semaglutide’s patent in March 2026, which is the active ingredient in weight-loss drugs, is likely to make room for new Brazilian competitors.
8. What role do São Paulo companies play in Brazil’s health sovereignty?
Brazil’s health sovereignty depends on pharmaceutical companies based in São Paulo. More than 90% of the medicines made in Brazil are made by Brazilian-owned companies. The acquisition of EMS-Medley makes it even easier for the US to control the supply of essential medicines. “It is also a matter of sovereignty,” said Alanac’s president. “The national industry should supply medicines to its people.”
